|
Oncolytics has completed seven clinical trials with REOLYSIN® in Canada, the U.K. and the U.S. and is currently conducting six Phase I or Phase II REOLYSIN® trials in the U.K. and the U.S. The Company has also received approval to begin a combination REOLYSIN® and cyclophosphamide trial in the U.K.
The current clinical program includes local or systemic delivery of REOLYSIN® as a monotherapy, and local or systemic delivery of REOLYSIN® in combination with radiation, chemotherapy or immune modulation for patients with advanced cancers.
|
